Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
  • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
  • A61K31/37—Coumarins, e.g. psoralen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the present invention relates to a method and composition for treating viral infection including a method and composition that targets an Angiotensin Converting Enzyme (ACE2) active site in a host or patient to thereby treat, prevent or limit the occurrence of the viral infection.
• ACE2 Angiotensin Converting Enzyme
• viruses Many human diseases result from infection by microscopic organisms called viruses. Infection by viruses can give rise to symptoms that vary from mild to severe. Viral infections can result in large numbers of deaths. Examples of such pandemics include the Spanish flu of 1918-1919 that killed approximately 40 million people and the HIV/AIDS epidemic that has killed almost 2 million people.
• Viruses require host organisms in order to replicate and viruses are transmitted from an infected host to an uninfected host through a number of mechanisms.
• a virus will first attach itself to a host cell. It will then enter the cell and release its genetic code (i.e., RNA or DNA). The virus makes use of the host cell's functional proteins and enzymes in order to replicate. Eventually, the host cell may die because the mechanisms it needs to survive are controlled by the virus. After death of the cell, the replicated viruses are released, allowing them to attack new host cells and continuing the replication process.
• Some viruses cause modification of the host cells leading to cancer, while other viruses can remain dormant in the host for an extended period prior to the infection becoming symptomatic in the host.
• the symptoms that result from viral infections can vary from virus-to- virus as any one virus typically will infect only certain types of cells. This observation also means that a specific virus will typically infect only certain species, although mutation of a virus can allow it to extend the number of species that any one virus is able to infect.
• cytokines such as the interferons (for example IL 1 , IL 6, IL 12, IL 16), tumor necrosis factor (TNF-a), and interferons (typically interferons a and g).
• interferons for example IL 1 , IL 6, IL 12, IL 16
• TNF-a tumor necrosis factor
• interferons typically interferons a and g.
• the role of these cytokines is to increase the resistance of other host cells to the invading virus. Many of the symptoms of viral infection experienced by the host results from the extensive release of cytokines, commonly referred to as the cytokine storm.
• the white blood cells are able to remember how to combat viruses that have previously invaded the body. So if the host survives the initial attack of the virus, the immune system is able to respond much more quickly to subsequent infections of the same virus.
• the body has developed an immunity to the virus. Such immunity can also be induced by presenting the immune system with a surrogate (vaccine) for the virus in a process known as immunization.
• vaccine surrogate
• Antiviral drugs are known in the art to assist the immune system in overcoming a viral infection in a patient. Most antiviral drugs work by slowing the replication of the virus in the infected patient's body thus allowing the body's immune system to launch an effective response when the disease symptoms are less severe. Antiviral drugs may work specifically on one or two viruses or may be effective across a broad spectrum of viruses. There are many known mechanisms by which antiviral agents can slow viral replication. One antiviral strategy is to slow or prevent the virus infiltrating a target cell, for example by binding to a receptor on the target cell which is required by the virus to enter the cell or by coating the virus so preventing its ability to bind to the target receptor(s). Other antiviral agents can slow viral replication once the virus particle has entered the target cell. Such mechanisms are well known in the art. SUMMARY OF THE INVENTION
• the present invention relates to methods and compositions for treating or limiting the occurrence of viral infection using compositions including pharmaceutical compositions that target the Angiotensin Converting Enzyme (ACE2) active site for the treatment, prevention or limiting the occurrence of infection.
• the infection and disease conditions and syndromes are caused by viruses and the present treatment addresses the disease conditions and syndromes produced by the viral infection.
• Possible viral infections (and their related disease conditions/syndromes) for which targeting the ACE2 active site treat include but are not limited to respiratory viruses and their related disease conditions or syndromes, such as those caused by coronaviruses including but not limited to COVID-19.
• the present invention relates to methods and compositions for treating viral diseases using various formulations which include but are not limited to those of granted U.S. Patents Nos. 8,034,838; 10,123,991 ; and 10,383,842 and pending applications U.S. Serial Nos. 16/302,292 and 16/544,308; all herein incorporated by reference.
• the present invention relates to the use of compositions, pharmaceutical agents and the like which are effective antiviral agents to treat, prevent, or limit the occurrence of various infection diseases including viruses such as but not limited to influenza, rhinovirus and coronaviruses.
• therapeutic treatment of individuals suffering from an infection by one or more coronavirus including the COVID-19 coronavirus includes those pharmaceutical agents (compounds and compositions) which the target ACE2 active site.
• present method and treatment using the aforementioned compounds and compositions disclosed in the above-cited patents/applications are especially suitable to making an individual less susceptible to a corona infection via ACE2 based on the currently understood way in which the coronavirus is pathogenic.
• the coronavirus presents a unique challenge in that it appears to exploit a ‘hand shake’ docking site to human cellular membranes that is atypical of influenza and rhinovirus. Influenza attaches to the cell membranes of a host (e.g., human) through the use of ICAM or intercellular adhesion molecules to download (insert) its genetic material. It is now becoming clear that the present strain of coronavirus (i.e., COVID-19) is hijacking the ACE2 or Angiotensin Converting Enzyme pathway to accomplish the same goal. The issue or challenge is that ACE2 is essential for maintaining the health of the pulmonary system and may not be a straightforward target for inhibition.
• the pharmaceutical composition comprises compounds of Formula I, Formula II, and Formula III including Formula Ilia and Formula lllb having the chemical structure as follows:
• the present invention in one advantageous form is directed to a method for treating or limiting the occurrence of viral infection and includes administering a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula I.
• the method in one advantageous form includes the composition having an effective amount for treating a virus by targeting the Angiotensin Converting Enzyme (ACE2) active site for the treatment, prevention or limiting occurrence of infection.
• ACE2 Angiotensin Converting Enzyme
• the viral infection is caused by COVID-19.
• the present invention in another advantageous form is directed to a method for treating or limiting the occurrence of viral infection by administering a therapeutically effective amount of a pharmaceutical composition comprising Formula II.
• the present invention in yet another advantageous form is directed to a method for treating or limiting the occurrence of a viral infection by administering a therapeutically effective amount of a pharmaceutical composition comprising Formula III.
• the present invention in one advantageous form comprises Formula III having a chemical structure selected from Formula Ilia and Formula I lib.
• the present invention in still yet another form is directed to a method of treating viral infection with a therapeutically effective composition selected from the group consisting of Formula I, Formula II, Formula III, Formula Ilia, and Formula lllb further comprising hesperidin and piperine.
• Naturally occurring when referring to a compound means a compound that is in a form in which it can be found naturally. A compound is not in a form that is naturally occurring if, for example, the compound has been purified and separated from at least some of the other molecules that are found with the compound in nature.
• a “naturally occurring compound” refers to a compound that can be found in nature, i.e., a compound that has not been created or modified by man.
• Treating refers to curing as well as ameliorating at least one symptom of the condition or disease.
• therapeutic effect is art-recognized and refers to a local or systemic effect in animals, particularly mammals, and more particularly humans caused by a pharmacologically active substance.
• therapeutically effective amount means that amount of such a substance that produces some desired local or systemic effect at a reasonable benefit/risk ratio applicable to any treatment.
• the therapeutically effective amount of such substance will vary depending upon the patient and disease or condition being treated, the weight and age of the patient, the severity of the disease or condition, the manner of administration and the like, which can readily be determined by one or ordinary skill in the art.
• certain compositions described herein may be administered in a sufficient amount to produce a desired effect at a reasonable benefit/risk ratio applicable to such treatment.
• a therapeutically effective amount is an amount that will target the Angiotensin Converting Enzyme (ACE2) active site for the treatment, prevention or limiting occurrence of infection including but not limited to viral infects caused by coronavirus including COVID-19.
• ACE2 Angiotensin Converting Enzyme
• pharmaceutically acceptable carrier means a carrier or diluent that does not give a stimulus to an organism and destroy the natures and bioactivities of an administered compound.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Virology (AREA)
• Molecular Biology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=77768366

Family Applications (1)

Country Status (9)

Cited By (1)

Families Citing this family (1)

Citations (3)

Family Cites Families (10)

• 2021
  • 2021-03-16 BR BR112022018504A patent/BR112022018504A2/pt not_active Application Discontinuation
  • 2021-03-16 AU AU2021236622A patent/AU2021236622A1/en active Pending
  • 2021-03-16 KR KR1020227035956A patent/KR20230012469A/ko not_active Ceased
  • 2021-03-16 JP JP2022555887A patent/JP2023518390A/ja active Pending
  • 2021-03-16 WO PCT/US2021/022538 patent/WO2021188520A1/en not_active Ceased
  • 2021-03-16 CN CN202180025427.5A patent/CN115397410A/zh active Pending
  • 2021-03-16 CA CA3172162A patent/CA3172162A1/en active Pending
  • 2021-03-16 US US17/911,455 patent/US20230132782A1/en not_active Abandoned
  • 2021-03-16 EP EP21771167.0A patent/EP4121040A4/en active Pending

Patent Citations (3)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events